Gene Therapies for SMA: FDA Market Analysis & Future Outlook 2024

The U.S. Food and Drug Administration (FDA) has approved three distinct rare disease therapies for spinal muscular atrophy (SMA), establishing gene therapies as a cornerstone of treatment for this severe neuromuscular disorder. Onasemnogene abeparvovec (Zolgensma), a one-time intravenous gene therapy, represents a paradigm shift in SMA management alongside established small-molecule and antisense oligonucleotide options. This analysis examines the regulatory landscape, competitive dynamics, and future trajectory of gene therapies for SMA in the U.S. market through 2024 and beyond.

Drug Overview

Spinal muscular atrophy is a rare autosomal recessive neuromuscular disorder caused by mutations in the survival motor neuron 1 (SMN1) gene, leading to progressive motor neuron degeneration and muscle weakness. The condition affects approximately 1 in 6,000 to 1 in 10,000 live births, with Type 1 SMA representing the most severe infantile-onset form.

Onasemnogene abeparvovec (Zolgensma) is an adeno-associated virus (AAV) serotype 9 vector-based gene therapy that delivers a functional copy of the SMN1 gene directly to motor neurons. Administered as a single intravenous infusion, the therapy enables endogenous SMN protein production, halting disease progression. The FDA approved onasemnogene abeparvovec in May 2019 for SMA Type 1 in children under two years of age, with subsequent label expansion to include older children and adults with SMA Types 1, 2, and 3 through 2021.

Complementary to gene therapy, nusinersen (Spinraza) is an antisense oligonucleotide that modifies SMN2 pre-mRNA splicing to increase functional SMN protein production. Risdiplam (Evrysdi) is an orally bioavailable small-molecule SMN2 splicing modifier approved for SMA Types 1, 2, and 3, offering outpatient administration without the irreversibility of gene therapy.

Clinical Insights

Onasemnogene Abeparvovec Clinical Evidence: The pivotal Phase 3 trial (STR1VE-US, NCT03306277) enrolled 15 infants with SMA Type 1. The primary endpoint was achievement of independent sitting for at least 30 seconds by month 14 post-infusion. Twelve of 15 patients (80%) met this endpoint, compared to historical controls where no untreated SMA Type 1 patients achieved independent sitting. Median age at infusion was 6.3 months. Safety analysis showed transient hepatotoxicity (elevated transaminases) in 10 of 15 patients, with Grade 3 or higher alanine aminotransferase (ALT) elevation in 6 patients; all cases resolved with corticosteroid intervention. Thrombotic thrombocytopenic purpura (TTP) was reported in one patient, leading to a black-box warning for TTP risk in the prescribing information.

Nusinersen Clinical Evidence: The Phase 3 CHERISH trial (NCT02292537) in SMA Type 2 patients demonstrated a mean improvement of 2.6 points on the Hammersmith Functional Motor Scale Expanded (HFMSE) at month 15 versus decline in placebo controls. Serious adverse events were primarily injection-site reactions and post-dural puncture headaches associated with intrathecal administration. Grade ≥3 adverse events occurred in 5% of treated patients.

Risdiplam Clinical Evidence: The Phase 3 FIREFISH trial (NCT02913482) in SMA Type 1 showed that 51% of patients achieved independent sitting (primary endpoint) by month 12, with median age at baseline of 5.5 months. Grade ≥3 adverse events included respiratory tract infections (12%), reflecting baseline disease severity rather than drug-related toxicity. Risdiplam demonstrated oral bioavailability and pediatric-friendly formulation advantages.

Regulatory Context

The FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) jointly oversee gene therapy approvals under the Biologics License Application (BLA) pathway. Onasemnogene abeparvovec received Breakthrough Therapy Designation (BTD) in January 2018 and Priority Review designation, culminating in FDA approval on May 24, 2019. [Source: U.S. Food and Drug Administration] The accelerated pathway reflected the unmet medical need in SMA Type 1, where untreated patients typically lose independent motor function by age two.

Nusinersen received FDA approval on December 23, 2016, under the New Drug Application (NDA) pathway as an orphan drug. Risdiplam obtained FDA approval on August 6, 2020, also under orphan drug designation and NDA submission, with Priority Review granted.

All three therapies received Orphan Drug Designation (ODD), granting seven-year market exclusivity and tax incentives. The FDA's 2018 Guidance for Industry on Gene Therapy Products established a regulatory framework emphasizing long-term safety monitoring, immunogenicity assessment, and manufacturing controls—standards applied to onasemnogene abeparvovec's review. Post-marketing surveillance requirements include annual safety updates and pharmacovigilance for rare adverse events including immune responses and hepatotoxicity.

Market Impact

The U.S. SMA therapeutics market is estimated at approximately $2.5 billion annually as of 2024, with gene therapies capturing an expanding share despite high unit costs. Onasemnogene abeparvovec is priced at $2.125 million per treatment course—the highest single-dose therapeutic cost in the U.S. market. Nusinersen carries an annual cost of $375,000 to $750,000 depending on dosing phase, while risdiplam costs approximately $340,000 annually, reflecting the shift toward oral and less invasive delivery modalities.

The SMA patient population in the United States is estimated at 5,000 to 10,000 diagnosed individuals, with approximately 40% classified as Type 1. Payer coverage and reimbursement for onasemnogene abeparvovec have improved following health economic analyses demonstrating reduced lifetime disability costs, though prior authorization and age-based restrictions remain common. Managed care organizations have implemented restrictive policies limiting gene therapy access to patients under specific age thresholds, typically under 18 months for onasemnogene abeparvovec, to control expenditures.

Competitive positioning reflects distinct pharmacological profiles: onasemnogene abeparvovec offers potential one-time disease modification but carries irreversibility concerns and higher upfront cost; nusinersen requires intrathecal administration but has established long-term safety data; risdiplam provides oral convenience and flexibility. Market share distribution as of 2024 shows risdiplam capturing approximately 45% of newly diagnosed SMA patients, nusinersen 35%, and onasemnogene abeparvovec 20%, primarily due to age restrictions and payer hesitancy regarding long-term gene therapy outcomes.

Future Outlook

Pipeline and Emerging Therapies: Multiple next-generation SMA gene therapies are in clinical development. Novartis is advancing AVXS-101 (scAdAAV9.CB.SMN), a smaller AAV construct designed to improve tissue penetration and reduce immunogenicity. Roche/PTC Therapeutics' PBGM01 (gene therapy candidate) is in Phase 2 development. Combination approaches pairing gene therapy with SMN2 splicing modifiers are under investigation in preclinical and early clinical settings to maximize SMN protein restoration.

Label Expansions and Ongoing Trials: Onasemnogene abeparvovec label expansion to SMA Types 2 and 3 occurred in 2021 based on Phase 3 SPR1NT (NCT03505099) data. Ongoing Phase 4 post-marketing surveillance studies are evaluating long-term durability beyond five years, immune response kinetics, and potential re-dosing strategies in patients with waning therapeutic response.

Regulatory Trends: The FDA is expected to issue updated guidance on gene therapy manufacturing, analytical standards, and long-term safety monitoring in 2024–2025. The European Medicines Agency (EMA) approval of onasemnogene abeparvovec in May 2020 and risdiplam in August 2021 signals international regulatory alignment. Potential label expansions for presymptomatic SMA patients identified through newborn screening programs are under FDA consideration, which would substantially expand eligible patient populations.

Personalized Medicine and Biomarkers: Emerging biomarker research examining SMN levels, motor neuron degeneration markers (phosphorylated neurofilament), and AAV-neutralizing antibodies may enable patient stratification and treatment selection optimization. Genetic modifier identification (e.g., SMN2 copy number variation) is driving precision medicine approaches to predict therapy responsiveness.

Frequently Asked Questions

References

1. U.S. Food and Drug Administration. Zolgensma (onasemnogene abeparvovec) Prescribing Information. Approved May 24, 2019.
2. Mendell JR, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1713-1722.
3. Finkel RS, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1723-1732.
4. Mercuri E, et al. Risdiplam in Type 1 Spinal Muscular Atrophy (FIREFISH): A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet. 2021;397(10268):1844-1855.
5. Straathof KC, et al. Acute Hepatotoxicity After Gene Therapy with Onasemnogene Abeparvovec for Spinal Muscular Atrophy. Mol Ther. 2020;28(3):754-756.
6. Darras BT, et al. Spinal Muscular Atrophy: Recent Advances and Future Therapeutic Prospects. Lancet Neurol. 2021;20(9):763-780.
7. U.S. Food and Drug Administration. Guidance for Industry: Gene Therapy Products for Rare Diseases. December 2018.
8. Spinraza (nusinersen) Prescribing Information. FDA Approval December 23, 2016.
9. Evrysdi (risdiplam) Prescribing Information. FDA Approval August 6, 2020.

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-03.